ClinicalTrials.gg
Not yet recruitingNCT07897461Updated Oct 27, 2026

Wearable Ankle Power Training (WearAPT) for Enhanced Mobility in Aging

An interventional study of Wearable Ankle Power Training (WearAPT) and Control in Sedentary Behavior / Physical Inactivity and Aged, sponsored by University of North Carolina, Chapel Hill. Not yet recruiting at 2 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Treatment

Updated Oct 27, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

This project introduces and investigates the scientific premise that passive wearable therapeutic devices can enhance plantarflexor muscle performance during walking to elicit and promote lasting physiological and functional improvements for older adults. The investigators aim to quantify the preliminary efficacy of wearable plantarflexor resistance training to enhance gait performance in older adults, investigate neural and muscular mechanisms of adaptation, and identify target candidate characteristics for personalized treatment strategies. The investigators will test the hypothesis that, compared to baseline and unlike controls, WearAPT will increase peak ankle power output, stride length, habitual and maximum walking speeds, walking economy, and 6-min walk distance.

Read the detailed description

This proposal will address the critical need for novel and evidence-based therapeutics to enhance muscle function, mobility, and independence to those in our rapidly aging population. Walking disability in older adults is characterized by shorter steps, slower habitual walking speeds, and higher metabolic energy costs. These functional impairments stem from precipitous reductions in ankle (plantarflexor) push-off power output that cannot be improved by conventional strength training. Motivated by the need to overcome the poor compliance and functional transfer of traditional interventions and the extraordinary cost of powered exosuits, the investigators contend that smart passive devices providing targeted ankle resistance have the potential to revolutionize wearable therapeutics for context-specific adaptation of the plantarflexor muscles during walking to elicit and promote lasting physical and functional improvements for older adults. The investigators will complete a multi-site, blinded, pilot randomized controlled trial (RCT) to quantify the efficacy of a 6-week Wearable Ankle Power Training (WearAPT) intervention with push-off biofeedback to enhance gait performance in older adults while: (i) gaining muscular and neural insight into mechanisms of adaptation and (ii) identifying target candidate characteristics toward the development of personalized treatment strategies.

The investigators will recruit n=36 slow walking (≤1.1 m/s) and inactive older adults with self-reported physical ability limitations at each of two sites, randomly assigned to WearAPT (20 min twice weekly for a total of 12 training sessions) or a control group participating in intensity-matched treadmill walking alone. A mixed factorial analysis (group assignment, time) will examine differences both pre- and post-intervention and at a +3-month follow-up visit.

02

Conditions studied

  • Sedentary Behavior / Physical Inactivity
  • Aged

Browse trials for

Keywords

  • Exoskeleton
  • Gait
  • Ankle
  • Assistive Technologies
  • Plantarflexor
  • Inactive older adults
  • Slow-walking older adults
03

In context

Sedentary Behavior

375 studies on the registry are indexed under Sedentary Behavior; 165 are open to participants now.

This study's planned enrollment of 72 is close to the median of 70 across 322 interventional studies indexed under Sedentary Behavior.

Browse Sedentary Behavior studies →

Lead sponsor

University of North Carolina, Chapel Hill is the lead sponsor of 1,370 studies on the registry; 133 are open to participants now.

Of its 160 completed or terminated interventional studies of FDA-regulated products, 139 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • insufficient weekly physical activity levels (i.e., ≤150 minutes moderate-intensity or ≤75 minutes vigorous-intensity activity)
  • self-select a habitual walking speed deemed indicative of age-related slowing (i.e., ≤1.1 m/s)
  • self-report at least some physical ability limitations (i.e., ≥4 on the "Stay Independent" questionnaire).

Exclusion criteria

Exclusion Criteria:

  • leg injury or fracture within the last 6 months
  • diagnosed anemia
  • neurological disorder of the legs such as peripheral neuropathy
  • vascular disorder of the legs such as peripheral arterial disease
  • taking medication that causes dizziness
  • cannot walk without an assistive aid (i.e., cane or walker)
  • Mini Mental State Exam ≤25
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    WearAPT

    Wearable ankle power training via resistive exoskeleton with push-off biofeedback

    Other: Wearable Ankle Power Training (WearAPT)

  • Active comparator
    Control

    Dose and intensity matched treadmill walking alone

    Other: Control

Interventions

  • OtherWearable Ankle Power Training (WearAPT)

    Participants will complete two supervised, 20-min WearAPT sessions per week over the 6-week intervention period. Informed by a pilot study and designed to ensure a standardized starting point for all participants, all subjects will initially begin their first visit walking at their baseline preferred (self-selected) treadmill walking speed, and with 0 Nm of ankle resistive torque. The investigators will increase the resistance by 0.025 Nm/kg per minute, up to a maximum of 0.15 Nm/kg on the first session. On subsequent sessions, walking speed and resistance will be increased based on two evidence-based criteria monitored in 5-min intervals: (i) rate of perceived exertion (RPE) between 4 and 6, and (ii) a target heart rate indicative of moderate intensity activity (i.e., 50-70% maximum heart rate). The investigators will increase walking speed by 2.5% per session and resistive torque by 0.025 Nm/kg per week.

    Also known as: Resistive ankle exoskeleton

  • OtherControl

    Participants randomly assigned to the control group will participate in pre- and post- laboratory visits and will complete a protocol of dose- (i.e., 20 min) and intensity-matched (i.e., heart rate) unresisted treadmill walking alone. Specifically, control participants will walk at a speed designed to elicit the same target within-session heart rate (i.e., 50-70% maximum).

06

What researchers measure

Primary outcomes

  1. Habitual Walking Speed (m/s)

    Average preferred walking speed during a 10-meter walk

    Time frame: Baseline, Week 7, Week 19

  2. 6-min Walk Test Distance (m)

    Maximum distance walked in 6 minutes

    Time frame: Baseline, Week 7, Week 19

  3. Walking Stride Length (m)

    Average stride length during walking at habitual speed

    Time frame: Baseline, Week 7, Week 19

  4. Calf Muscle Size (cm)

    Average plantarflexor cross-sectional area will be computed using ultrasound

    Time frame: Baseline, Week 7, Week 19

  5. Calf muscle strength (N/kg)

    Maximum strength of the plantarflexor muscles measured using a dynamometer

    Time frame: Baseline, Week 7, Week 19

  6. Calf muscle excitation

    The magnitude of habitual plantar flexor muscle activation during walking will be computed using recording electrodes (i.e., electromyography)

    Time frame: Baseline, Week 7, Week 19

Secondary outcomes

  1. Peak ankle power output (W/kg)

    Quantitative motion capture and inverse dynamics will compute the peak net ankle power output extracted from the push-off phase of walking.

    Time frame: Baseline, Week 7, Week 19

Other outcomes

  1. Walking Economy (W/kg)

    Net metabolic power estimated via expired gases during walking

    Time frame: Baseline, Week 7, Week 19

  2. Muscle coordination

    The investigators will compute changes in the relative weighting of activation of the major plantarflexor muscles compared to more proximal leg muscles.

    Time frame: Baseline, Week 7, Week 19

07

Study locations

2 sites
  • Biomechatronics Laboratory
    Flagstaff, Arizona 86011, United States
  • Applied Biomechanics Laboratory
    Chapel Hill, North Carolina 27599, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Mar 2030, 38 months later.

Of 250 non-industry interventional studies with no phase under Sedentary Behavior, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 38 months is above that.

Counting every sponsor, half of 253 studies reached it within 22 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2026
First posted
Oct 27, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Mar 1, 2030
CompletionEst.
Mar 1, 2030
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07897461
Responsible party
Sponsor
First posted
Oct 27, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Mar 1, 2030 (estimated)
Completion
Mar 1, 2030 (estimated)
Last update
Oct 27, 2026

Study contacts

Jason R Franz, PhD
Contact
jrfranz@email.unc.edu
919-966-6119
Jason Franz, PhD
principal investigator · University of North Carolina, Chapel Hill

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion